Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

NCCN Panel Develops Guidelines for Cancer-Related Fatigue

July 1, 2000
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

FORT LAUDERDALE, Fla-Despite the prevalence of fatigue in cancer patients and survivors, a number of obstacles have stood in the way of its successful treatment, said Barbara F. Piper, DNSc, RN, associate professor, University of Nebraska Medical Center College of Nursing. Patients have been reluctant to bring the symptom to their doctor’s attention out of a concern that they may look like “complainers” or that attending to the symptom will somehow interfere with their cancer treatment.

FORT LAUDERDALE, Fla—Despite the prevalence of fatigue in cancer patients and survivors, a number of obstacles have stood in the way of its successful treatment, said Barbara F. Piper, DNSc, RN, associate professor, University of Nebraska Medical Center College of Nursing. Patients have been reluctant to bring the symptom to their doctor’s attention out of a concern that they may look like “complainers” or that attending to the symptom will somehow interfere with their cancer treatment.

Physicians also have been stymied in their attempts to treat fatigue. The physiological basis of fatigue is poorly understood, and many proposed interventions have not been systematically studied. “It’s very difficult for us as providers to bring up something that we’re not quite sure we can treat,” Dr. Piper said.

To address these issues, the National Comprehensive Cancer Network (NCCN) convened a panel of experts to create practice guidelines for cancer-related fatigue. The chair of the NCCN Fatigue Guidelines Panel, Victoria Mock, DNSc, director, Oncology Nursing Research, Johns Hopkins Comprehensive Cancer Center, and Dr. Piper presented the guidelines at the Fifth Annual NCCN conference.

In his introduction, Rodger Winn, MD, chair of the NCCN Adult Guidelines Steering Committee, described the study of cancer-related fatigue as “a whole new field and discipline of medicine.”

Prevalence of Fatigue

Fatigue affects 70% to 100% of patients who are receiving cytotoxic chemotherapy, radiation therapy, or biologic response modifiers, Dr. Mock said. The guidelines describe cancer-related fatigue as “an unusual, persistent, subjective sense of tiredness related to cancer or cancer treatment that interferes with usual functioning.”

Fatigue went unrecognized for many years until practitioners got better control over the more acute symptoms of nausea, vomiting, and pain. With those symptoms well-managed by medication, patients now describe fatigue as the “most distressing” symptom associated with cancer and its treatment, according to several studies, Dr. Mock said.

Fatigue affects survivors as well as patients in active treatment, Dr. Piper noted. “It’s just beginning to be recognized as lasting longer than the treatment period,” she said.

Screening for Fatigue

The NCCN treatment pathway advises clinicians to screen for fatigue on the initial visit and periodically thereafter, asking patients to rate their fatigue on a 0 to 10 scale or describe their fatigue as “mild, moderate, or severe.”

When the fatigue is rated 4 and over, or as moderate or severe, the provider should do a more focused history and physical, Dr. Piper said. This assessment will determine whether the fatigue has progressed and whether there have been associated or alleviating factors. Of particular significance is whether fatigue is interfering with daily activities.

Fatigue may very well be the result of other symptoms. “Fatigue commonly clusters with sleep disturbance, anemia, emotional distress (ie, depression), and pain,” Dr. Piper said, and may be related to hypothyroidism. “If these primary factors are present, by all means treat the underlying cause of the fatigue.”

The primary evaluation also calls for an assessment of the patient’s comorbid-ities, nutritional status, and medications. The provider should also determine whether the patient has an exercise program. Patients who complain of fatigue may have been counseled to get more rest rather than to exercise more. “If they’re not exercising, this can lead to the disuse syndrome that we all know from our cardiac rehab days,” Dr. Piper said.

Interventions

Exercise, improved sleep habits, and better nutrition were among the non-pharmacologic interventions recommended. Of these recommendations, exercise has the strongest evidence base, Dr. Mock said. “Exercise increases functional capacity, leading to a reduced effort and decreased fatigue,” she said.

Walking, riding a stationary bicycle, and other forms of exercise were represented in the eight studies conducted with cancer patients and survivors that she cited. “These studies are limited in number because exercise has been a novel idea for cancer patients, and the work has progressed slowly,” she said.

She added that all of the exercise studies demonstrated significantly lower fatigue and mood disturbance in patients who exercised during treatment, and also decreased sleep disturbance when that was included as an outcome.

Some patients, especially those with extensive disease, should be referred to physical therapy, Dr. Mock said. Any exercise program should be individualized to the patient’s needs and physical condition.

Restorative therapy, such as gardening, walking outdoors, or taking part in volunteer activities unrelated to illness, was also among the nonpharmacologic interventions recommended.

The panel eagerly awaits the completion of several ongoing clinical trials that are examining the effects of nonpharma-cologic interventions, Dr. Mock said. She added that these trials may lead to the development of more specific guidelines for exercise and other interventions.

Cause-specific therapies are also listed as interventions in the guidelines. Iron, blood transfusions, and erythropoietin (epoetin alfa, Epogen, Procrit) are appropriate interventions for anemic patients. Hypothyroidism should also be treated. Similarly, fatigue associated with depression may be resolved with antidepressants.

Although low-dose corticosteroids and psychostimulants have reportedly helped some patients with fatigue, “the panel was not really comfortable with the level of evidence for pharmacologic therapy for cancer patients . . . and [it] hesitated to recommend these until more research has been done in this area,” Dr. Mock commented.

In addition to recommending appropriate pharmacologic or nonpharma-cologic interventions, physicians can suggest coping strategies for fatigue. Energy conservation is important. “Give them permission to postpone all nonessential activities,” Dr. Piper said. “Counsel patients to focus on one activity at a time when they have the energy to do so.”

Music, television, reading, and socializing are all forms of distraction that may help. Intervention studies have also shown that stress management, including support groups, may be beneficial.

Articles in this issue

Couric Urges Doctors to Talk to Patients About Colon Cancer
Automated Imaging Notification System Close to Fail-Safe
Higher Dairy Consumption Linked to Prostate Cancer Risk
First-Year Funding of Early Detection Research Network Complete
Gritty Antitobacco Ads and More From Legacy Foundation
Tositumomab Effective for Low-Grade Follicular Lymphoma
New Awards Spotlight Courage of Cancer Survivors
Hospital Volume Shown to Predict Breast Cancer Outcome
New Drug Information Website
NCCN Presents Updated Colorectal Cancer Guidelines
Taxol Teamed With Herceptin Tested Against Prostate Cancer
Adding Paclitaxel to Adjuvant FAC in Operable Breast Cancer May Lower Risk of Recurrence
Trend Toward Improved Outcomes With 5-FU/LV Plus RhuMabVEGF in Colorectal Cancer
Weekly Taxol/Herceptin: 60% RR in Metastatic Breast Cancer
Colonoscopy vs Sigmoidoscopy in Asymptomatic Women

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Tim Cortese
June 13th 2025
Article

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

Russ Conroy
June 13th 2025
Article

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.

Adding Retifanlimab to Chemo Yields Clinical Benefit in Inoperable SCAC

Tim Cortese
June 13th 2025
Article

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.


The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

Roman Fabbricatore
June 13th 2025
Article

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Related Content

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Tim Cortese
June 13th 2025
Article

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

Russ Conroy
June 13th 2025
Article

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.

Adding Retifanlimab to Chemo Yields Clinical Benefit in Inoperable SCAC

Tim Cortese
June 13th 2025
Article

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.


The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

Roman Fabbricatore
June 13th 2025
Article

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.